Cefminox sodium
Based on 1 publication(s) in Google Scholar
Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits antibacterial activity. Cefminox sodium is a broad-spectrum, bactericidal cephalosporin antibiotic. Cefminox sodium also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ. Cefminox sodium upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium also prevents pulmonary arterial hypertension in rat model.
For research use only. We do not sell to patients.
- Purity : 99.83%
- CAS No.: 75498-96-3
- Formula: C16H20N7NaO7S3
- Molecular Weight:541.56
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) Cefminox sodium
MoreAll Antibiotic Isoforms
More
Biological Activity
Description
|
PPARγ |
IP Receptor |
Bacterial |
In Vitro
Cefminox sodium (Compound MT-141) (0.1-800 μg/mL) is more active against gram-negative and anaerobic bacteria than against gram-positive bacteria[1].
Cefminox sodium (10-50 μM, 48 h) significantly inhibits the hypoxia-induced cell proliferation dose-dependently in primary pulmonary artery smooth muscle cells (PASMCs) through the enhancement of both IP and PPARγ activities[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Primary pulmonary artery smooth muscle cells (PASMCs)
-
Concentration:10 and 50 μM
-
Incubation Time:48 h
-
Result:Increased PTEN mRNA levels.
Increased PTEN protein levels in both normoxic and hypoxic conditions.
Inhibited the Akt/mTOR signaling pathway through elevation of PTEN protein levels.
Inhibited cell growth by up-regulation PTEN expression and inhibiting Akt/mTOR signaling in PASMCs under hypoxic conditions.
In Vivo
Cefminox sodium (1-1000 mg/kg, s.c., single dose) gives dose-related serum levels in male Slc:ddY mice[1].
Cefminox sodium (160-320 mg/kg/day, i.v., single dose) significantly decreases mean pulmonary artery pressure (mPAP) in male SD rats with hypoxia-induced pulmonary hypertension (HPH)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male Sprague Dawley (SD) rats (150-200 g) with hypoxia-induced pulmonary hypertension (HPH)[2]
-
Dosage:160 and 320 mg/kg/day
-
Administration:Intravenous injection (i.v.) in tail, single dose
-
Result:Significantly decreased mean pulmonary artery pressure (mPAP) dose-dependently.
Significantly reversed hypoxia-induced pulmonary artery remodeling by decreasing the number of smooth muscle cells.
Increased the expression of PTEN compared with that in the normoxia or hypoxia (no treatment) groups.
Chemical Information
-
CAS No. 75498-96-3
-
Appearance Solid
-
Molecular Weight 541.56
-
Formula C16H20N7NaO7S3
-
Color White to off-white
-
SMILES
O=C(C(N12)=C(CSC3=NN=NN3C)CS[C@]2([H])[C@](OC)(NC(CSC[C@@H](N)C(O)=O)=O)C1=O)O[Na]
-
Synonyms
MT-141
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Heliyon
Cefminox sodium alleviates the high-fat high-sugar-fed mice's hepatic fatty accumulation via multiple pathways. [Abstract]2023 Nov 7;9(11):e21973. PMID: 38027801
Solvent & Solubility
In Vitro:
H2O : 83.33 mg/mL (153.87 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (92.33 mM); Clear solution; Need ultrasonic
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
How to Select a Suitable Non-Mouse Animal Model
Selecting a suitable non-mouse animal model is a structured decision based on the research question, required anatomy or physiology, disease mechanism, endpoint feasibility, translational relevance, and ethical justification. Non-mouse models are preferred when mice cannot reproduce key human-relevant features, such as organ size, surgical anatomy, cardiovascular physiology, neuroanatomy, immune features, pharmacology, toxicology, or long-term clinical procedures. Candidate species may include rats, rabbits, guinea pigs, ferrets, zebrafish, pigs, sheep, goats, dogs, cats, horses, and non-human primates, but each species must be justified by its specific scientific advantage rather than convenience or tradition. Unresolved questions include how to quantify translational superiority across species, how to balance increased biological relevance against higher ethical burden, and when human-derived systems or new approach methodologies should replace animal use.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Inouye S, et al. In vitro and in vivo antibacterial activities of MT-141, a new semisynthetic cephamycin, compared with those of five cephalosporins. Antimicrob Agents Chemother. 1984 Nov;26(5):722-9. [Content Brief]
[2]. Xia J, et al. Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats. Front Pharmacol. 2018 Feb 23;9:134. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 1.8465 mL | 9.2326 mL | 18.4652 mL | 46.1629 mL |
| 5 mM | 0.3693 mL | 1.8465 mL | 3.6930 mL | 9.2326 mL | |
| 10 mM | 0.1847 mL | 0.9233 mL | 1.8465 mL | 4.6163 mL | |
| 15 mM | 0.1231 mL | 0.6155 mL | 1.2310 mL | 3.0775 mL | |
| 20 mM | 0.0923 mL | 0.4616 mL | 0.9233 mL | 2.3081 mL | |
| 25 mM | 0.0739 mL | 0.3693 mL | 0.7386 mL | 1.8465 mL | |
| 30 mM | 0.0616 mL | 0.3078 mL | 0.6155 mL | 1.5388 mL | |
| 40 mM | 0.0462 mL | 0.2308 mL | 0.4616 mL | 1.1541 mL | |
| 50 mM | 0.0369 mL | 0.1847 mL | 0.3693 mL | 0.9233 mL | |
| 60 mM | 0.0308 mL | 0.1539 mL | 0.3078 mL | 0.7694 mL | |
| 80 mM | 0.0231 mL | 0.1154 mL | 0.2308 mL | 0.5770 mL | |
| 100 mM | 0.0185 mL | 0.0923 mL | 0.1847 mL | 0.4616 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.